Related Experiment Video
Updated: May 16, 2026
05:17
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicity
Seong Jun Park1, Hannah Baars, Stefanie Mersmann
1Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52056 Aachen, Germany.
Chemmedchem
|December 11, 2012
Abstract:
From insects to cancer: N-Cyano sulfoximines were evaluated for COX inhibition and antiproliferative activity against a panel of cancer cell lines. The most active compound exhibited potent COX-2 inhibition, some selectivity for COX-2 over COX-1, only slight cytotoxicity towards healthy cells (HaCaT skin cells), and no mutagenic potential (as determined by an Ames assay).
Insights
New N-Cyano sulfoximines show promise as anti-cancer agents. They effectively inhibit COX-2 enzymes and reduce cancer cell growth with minimal impact on healthy cells.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Cyclooxygenase (COX) enzymes, particularly COX-2, are implicated in inflammation and cancer development.
- Sulfoximines are a class of compounds with diverse biological activities.
- N-Cyano sulfoximines represent a novel chemical scaffold for drug discovery.
Purpose of the Study:
- To investigate the potential of N-Cyano sulfoximines as inhibitors of COX enzymes.
- To evaluate the antiproliferative effects of these compounds against various cancer cell lines.
- To assess the safety profile, including cytotoxicity and mutagenicity, of the most active compounds.
Main Methods:
- Synthesis and chemical characterization of N-Cyano sulfoximine derivatives.
- In vitro assays for COX-1 and COX-2 inhibition.
- Antiproliferative assays using a panel of human cancer cell lines.
- Cytotoxicity assessment on normal HaCaT skin cells.
- Bacterial reverse mutation assay (Ames test) for mutagenicity.
Main Results:
- One N-Cyano sulfoximine compound demonstrated potent inhibition of COX-2.
- This compound displayed selectivity for COX-2 over COX-1.
- Significant antiproliferative activity was observed against tested cancer cell lines.
- The lead compound showed minimal cytotoxicity towards HaCaT cells.
- No mutagenic potential was detected in the Ames assay.
Conclusions:
- N-Cyano sulfoximines are a promising class of compounds with dual potential for COX-2 inhibition and cancer treatment.
- The lead compound exhibits a favorable safety profile, warranting further investigation.
- These findings support the development of N-Cyano sulfoximines as novel therapeutic agents for cancer.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:11Aryldiazonium Salts to Azo Dyes: Diazo Coupling
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para position.
01:14Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...